Cytosorbents

What Cytosorbents does

CytoSorbents Corporation is a publicly traded (NASDAQ: CTSO) medical device company that develops and commercializes blood purification technologies built on a proprietary platform of biocompatible, highly porous polymer beads. The beads remove elevated levels of harmful substances from whole blood and other bodily fluids via hemoadsorption (pore capture and surface adsorption), and are deployed in cartridges compatible with standard hospital blood pumps including dialysis, CRRT, ECMO, and heart-lung machines.

The company's core product is CytoSorb, a CE-marked hemoadsorption device sold in over 70 countries and used primarily in critical care (sepsis, septic shock, cytokine storm) and cardiac surgery applications. The portfolio also includes the investigational DrugSorb-ATR antithrombotic removal system (two FDA Breakthrough Device Designations), the HotSwap cartridge exchange system launched at ISICEM 2026, the PuriFi standalone hemoperfusion pump (over 100 units placed internationally), the ECOS-300CY ex vivo organ perfusion system, and VetResQ for veterinary use. Pipeline products include HemoDefend-BGA (universal plasma, DoD-funded), HemoDefend-RBC, CytoSorb-XL, K+ontrol, and ContrastSorb.

CytoSorbents generates revenue through a hybrid commercial model combining a direct sales organization (primarily Germany and select international territories) with an extensive distributor network spanning 70+ countries. FY2025 revenue was $37.1M (+4% YoY) at 71% gross margins, with the distributor channel representing ~44% of revenue and growing 11.4%, while Germany direct sales declined 10% due to a 2025 restructuring. The company is pursuing FDA approval for DrugSorb-ATR in the U.S. and Canada following an August 2025 appeal denial, and is targeting cash flow breakeven in H2 2026 supported by a Q4 2025 ~10% workforce reduction.

Name

Cytosorbents

Legal name

CytoSorbents, Inc.

Website

https://cytosorbents.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

101–250 employees

Short description

CytoSorbents (NASDAQ: CTSO) develops and commercializes proprietary biocompatible polymer-bead hemoadsorption cartridges for blood purification in critical care and cardiac surgery, distributing in 70+ countries and pursuing FDA approval for its DrugSorb-ATR antithrombotic removal system.

Ownership category

akta.pro rank

Product category

Blood Purification Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges) (HLAHAKAH)

akta.pro secondary industries

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ), Blood Bank, Transfusion Medicine & Immunohematology (HLAHAAAH)

Keywords

• Blood purification devices
• Hemoadsorption therapy
• Critical care medical devices
• Extracorporeal blood treatment
• Cytokine removal cartridges

Headquarters

HQ city

Monmouth Junction

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. CytoSorb Device Sales: Revenue generated from sales of CytoSorb and related blood purification devices and cartridges. Full-year 2025 revenue of $37.1 million, up 4% year-over-year. Gross margins of 71% in 2025. Sold in over 70 countries with direct sales in Germany and select territories, and distributor sales globally.
2. PuriFi and Pump Sales: Sales of PuriFi hemoperfusion pumps and related accessories. Over 100 pumps placed internationally as of 2025 year-end, expanding the blood purification infrastructure to fuel device and disposables usage.
3. VetResQ Veterinary Products: CytoSorb technology designed for veterinary critical-care applications, available in the US market.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Core offering

CytoSorbents develops, manufactures, and commercializes blood purification medical devices based on proprietary biocompatible porous polymer bead technology. Its core product CytoSorb is a CE-marked hemoadsorption cartridge that removes cytokines, toxins, bilirubin, myoglobin, and antithrombotic drugs from blood, used in critical care, cardiac surgery, liver failure, and kidney injury. The company also sells the PuriFi hemoperfusion pump, the ECOS-300CY organ perfusion system, and the HotSwap rapid adsorber exchange system, and is developing the DrugSorb-ATR antithrombotic removal system for FDA approval.

Product overview

CytoSorbents is a blood purification technology company offering a portfolio of products based on proprietary biocompatible, highly porous polymer bead technology. The core product CytoSorb (CE-marked in the EU) is complemented by the investigational DrugSorb-ATR device seeking FDA approval for antithrombotic removal. Supporting products include HotSwap (rapid adsorber exchange system), PuriFi (standalone hemoperfusion pump), and ECOS-300CY (ex vivo organ perfusion). The company also develops VetResQ for veterinary applications and has pipeline products including HemoDefend-BGA, HemoDefend-RBC, and CytoSorb-XL. Products work with standard hospital blood pumps including dialysis, CRRT, ECMO, and heart-lung machines.

Differentiator

Problem solved

Functional benefit

Brands

• CytoSorb: CE-mark approved hemoadsorption device for blood purification in critical care and cardiac surgery
• DrugSorb-ATR
• HotSwap
• PuriFi
• ECOS-300CY
• VetResQ
• HemoDefend-BGA
• HemoDefend-RBC

Products and services

• CytoSorb 300 CE-marked blood purification device using biocompatible, highly porous polymer beads that remove toxic substances from blood by hemoadsorption. Used in critical care and cardiac surgery to reduce elevated levels of harmful compounds including cytokines, bilirubin, myoglobin, and drugs such as ticagrelor and rivaroxaban. CE mark approved in the EU with extensions for bilirubin and myoglobin removal.
• DrugSorb-ATR Investigational antithrombotic removal system using equivalent polymer bead technology to CytoSorb, designed to reduce severity of perioperative bleeding in cardiothoracic surgery patients on blood thinners. Holds two FDA Breakthrough Device Designations for ticagrelor removal and DOAC (apixaban/rivaroxaban) removal.
• HotSwap System enabling rapid exchange of CytoSorb adsorbers during critical care treatment, ensuring safe blood return from used devices and supporting delivery of the right therapy dose.
• PuriFi Hemoperfusion Pump Hemoperfusion pump system enabling independent CytoSorb therapy without dependence on other extracorporeal machines such as dialysis, CRRT, ECMO, or heart-lung machines. Over 100 pumps placed internationally as of 2025 year-end.
• ECOS-300CY Organ Perfusion System Ex vivo organ perfusion system working with CytoSorb technology to support management of inflammatory processes during organ preservation and perfusion procedures.
• VetResQ CytoSorb technology adapted for veterinary critical-care applications. Available only in the US through veterinary distribution channels.

Quantifiable outcome

• 300,000+ cumulative treatments delivered globally by end of 2025
• +7 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Two partnerships are on record, tiered core.

• Aferetica SrlcoreChannel Partner/ Reseller/ Distributor · 19 March 2026Renewed exclusive distribution partnership with Aferetica Srl in Italy during ISICEM 2026, extending collaboration spanning more than a decade. Partnership includes collaboration on Aferetica's PerLife organ perfusion platform. Aferetica serves as exclusive distributor for CytoSorb products in Italy.
• U.S. Department of Defense (U.S. Army Medical Research Acquisition Activity)coreStrategic or Co-development Partner · 9 September 2022Awarded nearly $2 million grant to develop HemoDefend-BGA adsorber to create universal plasma by removing anti-A and anti-B antibodies from blood plasma. Program includes two-year preclinical animal study to evaluate safety and efficacy before pursuing human trials. Represents strategic partnership for blood safety applications.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Nikkiso: Nikkiso manufactures CRRT and dialysis machines (Aquamax) for critical care settings and is a significant global competitor in extracorporeal blood purification equipment used alongside hemoadsorption therapies like CytoSorb.
• Baxter International: Baxter manufactures the Prismax CRRT system and dialysis equipment used in ICU settings where CytoSorb is integrated as an add-on cartridge, making Baxter the dominant platform provider whose installed base CytoSorb depends on.
• Asahi Kasei Medical: Asahi Kasei Medical manufactures leukocyte reduction filters, plasma fractionation products, and other blood purification technologies as part of a broader medical device portfolio, providing overlapping blood purification capabilities to hospitals and blood banks.
• B. Braun: B. Braun manufactures CRRT and hemodialysis equipment (Diapact, Dialog+) commonly used in European ICUs where CytoSorb is integrated, sharing the same hospital customer base and clinical workflows.
• Fresenius Medical Care: Fresenius Medical Care is the global leader in dialysis products and CRRT equipment (multiFiltrate, Omni), with installed base in hospitals worldwide where CytoSorb is deployed alongside their blood pumps.
• Terumo BCT: Terumo BCT manufactures blood component processing and cell therapy technologies, with overlapping capabilities in extracorporeal blood handling systems that intersect with CytoSorb's blood purification applications.
• Edwards Lifesciences: Edwards Lifesciences is a leader in cardiac surgery products including heart valves and hemodynamic monitoring, sharing the cardiac surgery customer base where DrugSorb-ATR is deployed for blood thinner removal during CABG procedures.

Direct peers

• Spectral Medical: Spectral Medical develops Toraymyxin, a polymyxin B hemoperfusion cartridge for endotoxin removal in septic shock, directly competing with CytoSorb's sepsis/septic shock indication with a similar blood-purification cartridge business model.
• Jafron Biomedical: Jafron is a leading Chinese manufacturer of hemoadsorption cartridges (HA series) used in critical care for cytokine and toxin removal, offering the most direct global competition to CytoSorb's core hemoadsorption technology.
• ExThera Medical: ExThera Medical manufactures the Seraph 100 Microbind Affinity Blood Filter, a hemoperfusion device that removes bloodborne pathogens, competing in the same extracorporeal blood purification cartridge category as CytoSorb for hospital critical care use.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/cytosorbents
• YouTubeyoutube.com/c/CytoSorb
• Facebookfacebook.com/cytosorbents
• LinkedInlinkedin.com/company/268519
• Instagraminstagram.com/cytosorbents_official

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries3 records

Funding overview

Funding rounds12 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytosorbents